Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed stage II or IIIA non-small cell lung cancer * T1-3, N1-2, M0 * No stage IIIB (e.g., contralateral N3), stage IV (M1), or T3, N0, M0 disease * N1 disease eligible only if hilar lymph node involvement present * No bronchoalveolar carcinoma with lobar or multilobar involvement * No small cell lung carcinoma, including mixed histology * No more than 7 weeks since prior surgery (lobectomy, sleeve resection, bilobectomy, or pneumonectomy) * Negative surgical margins * No incompletely resected gross disease OR * No microscopically positive bronchial or vascular margins * No known CNS metastasis PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-1 Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 2,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Not specified Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance greater than 60 mL/min Cardiovascular: * No superior vena cava syndrome Pulmonary: * FEV\_1 at least 1.0 L Gastrointestinal: * No prior celiac disease, familial polyposis, Turcot's syndrome, Gardner's syndrome, Peutz-Jegher's syndrome, or hereditary non-polyposis colon cancer * No prior colitis, inflammatory bowel disease, or pancreatitis within the past 10 years Other: * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * No known sensitivity to rodent proteins * No prior hypersensitivity or contraindication to study treatments (e.g., monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, aluminum hydroxide, or murine proteins) or any excipients * No prior clinically significant hypersensitivity reactions (e.g., angioedema, anaphylaxis, or serious dermatological manifestations) or asthmatic attacks requiring hospitalization * No prior immune or immunodeficiency disorders (e.g., HIV, sarcoidosis, tuberculosis, rheumatoid arthritis, or autoimmune disorders) * No prior seizure disorder requiring continuous medication * No active infection * No other prior or concurrent malignancy within the past 3 years except surgically treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer * No medical contraindication to surgery, radiotherapy, or immunotherapy * No prior drug or alcohol abuse (excluding nicotine) within the past 12 months * No prior psychiatric or addictive disorder that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior murine antibodies (e.g., OncoScint scan) * No prior monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, or other investigational carcinoembryonic antigen-derived therapy * At least 3 years since other prior immunotherapy * At least 30 days since prior immunization (e.g., influenza) * No immunomodulatory therapy (e.g., gold, auranofin, hydroxychloroquine, sulfasalazine, penicillamine, levamisole, dapsone, azathioprine, intravenous immunoglobulin, leukotriene antagonists, cromoglycate, ketotifen, nedocromil, psoralin-ultraviolet-light, or plasmapheresis) within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer Chemotherapy: * At least 3 years since prior chemotherapy except topical therapy * No concurrent methotrexate or cyclophosphamide Endocrine therapy: * At least 45 days since prior corticosteroids * No concurrent systemic corticosteroids Radiotherapy: * No prior thoracic radiotherapy Surgery: * See Disease Characteristics Other: * At least 45 days since prior immunosuppressants * No investigational agents within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer * No concurrent amifostine * No concurrent cyclosporine * No other concurrent immunosuppressants * No concurrent chronic systemic antihistamines